Physician profile
James Ko
NPI 1972773935
$19,220.95
in general payments reported to CMS, 2019-2025
71 companies · $4,139 in 2025
The $4,139 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $1,037 · 2021: $1,538 · 2022: $2,577 · 2023: $4,280 · 2024: $4,789 · 2025: $4,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,084.01 |
| Education | $124.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $3,769.16 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,241.47 | 2021-2025 | |
| Sk Life Science, INC. | $1,189.90 | 2021-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $841.23 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $796.87 | 2023-2025 | Lumryz |
| Neurocrine Biosciences, INC. | $758.55 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $715.79 | 2020-2025 | Vyepti, Rexulti |
| Pfizer INC. | $696.38 | 2021-2025 | |
| Harmony Biosciences LLC | $592.69 | 2020-2025 | Wakix |
| Amgen INC. | $573.23 | 2019-2025 | Uplizna |
| Lilly USA, LLC | $541.02 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Argenx US, INC. | $538.06 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $473.80 | 2021-2025 | Zeposia |
| Csl Behring | $366.58 | 2019-2025 | Hizentra |
| Emd Serono, INC. | $348.75 | 2019-2024 | Mavenclad |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $330.59 | 2023-2025 | Rexulti, Nuedexta |
| Biogen, INC. | $327.76 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Eisai INC. | $324.29 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $272.09 | 2019-2025 | Epidiolex |
| Axsome Therapeutics, INC. | $267.89 | 2023-2025 | Symbravo, Sunosi |
| Acadia Pharmaceuticals INC | $267.15 | 2019-2025 | Nuplazid |
| Inspire Medical Systems, INC. | $256.72 | 2024 | Inspire |
| Ucb, INC. | $222.40 | 2022-2025 | Briviact, Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $210.82 | 2020-2025 | Ultomiris |
| Kyowa Kirin, INC. | $201.70 | 2023-2025 | Nourianz |
| Aucta Pharmaceuticals, INC. | $192.27 | 2024-2025 | Motpoly Xr |
| Azurity Pharmaceuticals, INC. | $173.43 | 2023-2025 | Horizant, Horizant |
| Allergan, INC. | $155.72 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $151.76 | 2023-2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $144.48 | 2021-2023 | Ponvory |
| Neurelis, INC. | $140.04 | 2021-2025 | Valtoco |
| Mdd US Operations, LLC | $138.99 | 2022-2025 | Xadago, Apokyn, Apokyn |
| Janssen Biotech, INC. | $136.14 | 2025 | |
| Medtronic Vascular, INC. | $131.38 | 2019 | |
| Acorda Therapeutics, INC | $125.35 | 2019-2024 | Inbrija |
| Biohaven Pharmaceutical Holding Company LTD. | $122.03 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $120.93 | 2021-2025 | Wainua |
| Adamas Pharmaceuticals, INC. | $116.90 | 2019-2021 | |
| Tg Therapeutics, INC. | $112.79 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $109.30 | 2025 | Xeomin, Inbrija |
| W. L. Gore & Associates, INC. | $87.01 | 2021-2023 | Gore Cardioform Septal Occluder |
| Greenwich Biosciences, INC. | $70.64 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $64.03 | 2023-2024 | Ztlido |
| Ge Healthcare | $63.80 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $62.10 | 2024-2025 | Dysport |
| Genentech USA, INC. | $52.69 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $47.54 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $44.94 | 2022 | |
| Grifols USA, LLC | $43.25 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $42.73 | 2019 | |
| Octapharma USA, INC. | $39.92 | 2021-2022 | |
| Corium, LLC | $32.74 | 2023 | Azstarys |
| Almatica Pharma LLC | $30.02 | 2021-2023 | Gralise |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 2020 | |
| Amneal Pharmaceuticals LLC | $29.64 | 2020-2025 | Brekiya |
| Vertical Pharmaceuticals, LLC | $29.16 | 2019 | |
| Neuronetics, INC. | $26.19 | 2024 | Neurostar Tms Therapy System |
| Catalyst Pharmaceuticals, INC. | $25.99 | 2025 | |
| Assertio Therapeutics, INC. | $25.75 | 2020 | |
| Vanda Pharmaceuticals INC. | $18.36 | 2025 | Ponvory |
| Insightec,INC | $16.89 | 2025 | Exablate |
| Life Molecular Imaging LTD | $16.87 | 2024 | Neuraceq |
| Merck Sharp & Dohme LLC | $16.39 | 2023 | Belsomra |
| Supernus Pharmaceuticals, INC. | $15.05 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $15.00 | 2020 | |
| Upsher-Smith Laboratories LLC | $14.94 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.93 | 2021 | |
| Banner Life Sciences, LLC | $14.14 | 2023 | |
| Tris Pharma INC | $13.94 | 2022 | |
| Mallinckrodt Enterprises LLC | $12.59 | 2019 | |
| Impel Pharmaceuticals LLC | $7.31 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.